Table 3.
Treatment for the patients of uterine sarcoma
| histological types | ||||||
|---|---|---|---|---|---|---|
| Treatment | Total | LG-ESS | HG-ESS | UUS | LMS | AS |
| No. of patients(n/%) | 114 | 50(43.9) | 13(11.4) | 9(7.9) | 34(29.8) | 8(7.0) |
| Surgical procedures | 108(94.7) | 45(90.0) | 13(100) | 9(100) | 34(100) | 7(87.5) |
| Myomectomy▼ | 5(4.6) | 2(4.4) | 0 | 0 | 3(8.8) | 0 |
| AH | 79(73.1) | 29(64.4) | 10(76.9) | 9(100) | 25(73.5) | 6(85.7) |
| LH | 24(22.2) | 14(31.1) | 3(23.1) | 0 | 6(17.6) | 1(14.3) |
| BSO | 94(87.0) | 41(91.1) | 11(84.6) | 9(100) | 29(85.3) | 4(57.1) |
| PLND | 47(43.5) | 18(40.0) | 8(61.5) | 8(88.9) | 10(29.4) | 3(42.9) |
| OE | 20(18.5) | 7(15.6) | 4(30.8) | 3(33.3) | 5(14.7) | 1(14.3) |
| Adjuvant treatment | ||||||
| chemotherapy | 58(53.7) | 20(44.4) | 11(84.6) | 7(77.8) | 17(50.0) | 3(42.9) |
| radiotherapy | 19(17.6) | 9(20.0) | 3(23.1) | 0 | 6(17.6) | 1(14.3) |
| hormone therapy | 30(27.8) | 30(66.7) | 0 | 0 | 0 | 0 |
| Palliative chemotherapy or hormone therapy | 4(3.5) | 4(8.0) | 0 | 0 | 0 | 0 |
| Refuse treatment | 2(1.8) | 1(2.0) | 0 | 0 | 0 | 1(12.5) |
▼One patient in the LMS group was hysteroscopic myomectomy, and the rest of patients were open myomectomy; LG-ESS: low-grade endometrial stromal sarcoma; HG-ESS: high-grade endometrial stromal sarcoma; UUS: undifferentiated uterine sarcoma; LMS: leiomyosarcoma; AS: adenosarcoma; AH= abdominal hysterectomy; LH=laparoscopic hysterectomy; BSO=bilateral salping-oophorectomy; PLND=pelvic lymphadenectomy; OE=omentectomy.